Exosomes are cell-derived vesicles that are present in almost all eukaryotic fluids, including blood, urine, cerebrospinal fluid and cultured medium of cell cultures in vitro. First discovered around 50 years ago, it is only in the past 10 years or so that exosome research has picked up, with a 10-fold increase in the number of publications relating to exosomes between 2006 and 2017. 

GBI Research's latest report, 'Exosome Technologies: Recent Surge in R&D with Capricor, Codiak and Evox Therapeutics among Key Players' states that there are more than 20 products in active development within the exosomes pipeline across a number of therapy areas, including oncology, central nervous system, cardiovascular disease and infectious disease. 

The number of clinical trials involving exosome therapies has increased substantially in recent years. Since 2006, 124 clinical trials relevant to exosomes have been registered, the majority of which have been registered in the past three years.